Finnegan client Eli Lilly & Co. filed an infringement suit May 5 in the District of New Jersey against Zydus Pharmaceuticals “accusing it of breaching a consent order entered in a previous case Lilly brought over attention deficit hyperactivity disorder treatment Strattera®.” Lilly contends that Zydus willfully did not amend its ANDA to convert its patent certification from one under Paragraph IV to one under Paragraph III following the consent order's entry. Lilly is represented by Finnegan in this matter.
